PMID- 34333276
OWN - NLM
STAT- MEDLINE
DCOM- 20220112
LR  - 20220112
IS  - 1873-5835 (Electronic)
IS  - 0145-2126 (Linking)
VI  - 111
DP  - 2021 Dec
TI  - Survival among patients with composite and sequential lymphoma between primary 
      mediastinal lymphoma/diffuse large B-cell lymphoma and classical Hodgkin 
      lymphoma: A population-based study.
PG  - 106669
LID - S0145-2126(21)00170-3 [pii]
LID - 10.1016/j.leukres.2021.106669 [doi]
AB  - BACKGROUND: Data on composite and sequential lymphoma between primary mediastinal 
      lymphoma/diffuse large B-cell lymphoma (LBCL) and classical Hodgkin lymphoma 
      (cHL) are rare. METHODS: We identified 25 cases with composite lymphoma (CL), 116 
      cases developing LBCL as a second primary cancer after cHL (cHL-LBCL), and 74 
      cases developing cHL as a second primary cancer after LBCL (LBCL-cHL) from the 
      Surveillance, Epidemiology, and End Results (SEER) 18 database. Comparisons of 
      overall survival (OS) and lymphoma cause-specific survival (CSS) between patients 
      with cHL-LBCL or cHL-LBCL and their de novo counterparts were performed. RESULTS: 
      The 5-year OS of patients with CL was 74.8 %. No significant difference in 
      unadjusted OS and lymphoma CSS were observed between patients with de novo LBCL 
      (LBCL-1 group) and patients with cHL-LBCL. However, the age- and stage-adjusted 
      cHL-LBCL group had inferior OS and lymphoma CSS compared with that in the LBCL-1 
      group. The unadjusted and adjusted OS and lymphoma CSS in the LBCL-cHL group were 
      significantly worse than patients with de novo cHL. CONCLUSIONS: CL between LBCL 
      and cHL may have good outcomes. cHL survivors had poorer outcomes after a LBCL 
      diagnosis versus patients with LBCL-1. Significantly poor outcomes were observed 
      in patients with LBCL-cHL compared with patients with de novo cHL.
CI  - Copyright (c) 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Tao, Yunxia
AU  - Tao Y
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking 
      Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer 
      Molecular Targeted Drugs, Beijing, China.
FAU - Chen, Haizhu
AU  - Chen H
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking 
      Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer 
      Molecular Targeted Drugs, Beijing, China.
FAU - Liu, Dan
AU  - Liu D
AD  - Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical 
      University, Yunnan Cancer Center, Kunming, China.
FAU - Dai, Xiumei
AU  - Dai X
AD  - Department of Medical Oncology, Xuzhou Central Hospital, Clinical School of 
      Xuzhou Medical University, Xuzhou, China. Electronic address: xmdai_123@sohu.com.
LA  - eng
PT  - Journal Article
DEP - 20210716
PL  - England
TA  - Leuk Res
JT  - Leukemia research
JID - 7706787
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Chemoradiotherapy/*mortality
MH  - China/epidemiology
MH  - Female
MH  - Follow-Up Studies
MH  - Hodgkin Disease/epidemiology/*mortality/pathology/therapy
MH  - Humans
MH  - Lymphoma, Large B-Cell, Diffuse/epidemiology/*mortality/pathology/therapy
MH  - Male
MH  - Mediastinal Neoplasms/epidemiology/*mortality/pathology/therapy
MH  - Middle Aged
MH  - Neoplasms, Second Primary/epidemiology/*mortality/pathology/therapy
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Young Adult
OTO - NOTNLM
OT  - Classical Hodgkin lymphoma
OT  - Composite lymphoma
OT  - Population-based study
OT  - Primary mediastinal lymphoma/diffuse large B-cell lymphoma
OT  - Sequential lymphoma
EDAT- 2021/08/02 06:00
MHDA- 2022/01/13 06:00
CRDT- 2021/08/01 20:52
PHST- 2021/06/06 00:00 [received]
PHST- 2021/07/13 00:00 [revised]
PHST- 2021/07/15 00:00 [accepted]
PHST- 2021/08/02 06:00 [pubmed]
PHST- 2022/01/13 06:00 [medline]
PHST- 2021/08/01 20:52 [entrez]
AID - S0145-2126(21)00170-3 [pii]
AID - 10.1016/j.leukres.2021.106669 [doi]
PST - ppublish
SO  - Leuk Res. 2021 Dec;111:106669. doi: 10.1016/j.leukres.2021.106669. Epub 2021 Jul 
      16.